Risk-benefit profile of onasemnogene abeparvovec in older and heavier children with spinal muscular atrophy type 1.
Finnegan R, Manzur A, Munot P, Dhawan A, Murugan A, Majumdar A, Wraige E, Gowda V, Vanegas M, Main M, O'Reilly E, Baranello G, Muntoni F, Scoto M.
Finnegan R, et al. Among authors: muntoni f.
Neuromuscul Disord. 2024 Sep;42:22-26. doi: 10.1016/j.nmd.2024.07.004. Epub 2024 Jul 11.
Neuromuscul Disord. 2024.
PMID: 39111255